Jgp Global Gestao De Recursos Ltda Has Lifted Seattle Genetics (SGEN) Holding; The Dun & Bradstreet (DNB) Had 1 Analysts Last Week

December 7, 2017 - By Darrin Black

Among 6 analysts covering Dun & Bradstreet (NYSE:DNB), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Dun & Bradstreet had 10 analyst reports since November 4, 2015 according to SRatingsIntel. The firm has “Equal-Weight” rating by Barclays Capital given on Monday, November 13. The firm has “Hold” rating by Piper Jaffray given on Wednesday, August 2. The firm earned “Underweight” rating on Friday, February 10 by Barclays Capital. The company was maintained on Tuesday, July 25 by Stifel Nicolaus. The stock has “Buy” rating by Robert W. Baird on Monday, October 23. On Friday, January 20 the stock rating was upgraded by Goldman Sachs to “Neutral”. The stock has “Outperform” rating by Robert W. Baird on Friday, November 3. See The Dun & Bradstreet Corporation (NYSE:DNB) latest ratings:

13/11/2017 Broker: Barclays Capital Old Rating: Underweight New Rating: Equal-Weight Upgrade
08/11/2017 Broker: Goldman Sachs Rating: Neutral New Target: $125 Initiates Coverage On
03/11/2017 Broker: Robert W. Baird Rating: Outperform Old Target: $130 New Target: $127 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $130.0 Maintain
02/08/2017 Broker: Piper Jaffray Rating: Hold New Target: $118.0000 Maintain
25/07/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $112.0000 Maintain

Jgp Global Gestao De Recursos Ltda increased Seattle Genetics Inc (SGEN) stake by 205.21% reported in 2017Q2 SEC filing. Jgp Global Gestao De Recursos Ltda acquired 13,201 shares as Seattle Genetics Inc (SGEN)’s stock rose 1.68%. The Jgp Global Gestao De Recursos Ltda holds 19,634 shares with $1.02 million value, up from 6,433 last quarter. Seattle Genetics Inc now has $8.25B valuation. The stock increased 1.04% or $0.59 during the last trading session, reaching $57.34. About 204,316 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since December 7, 2016 and is uptrending. It has outperformed by 58.98% the S&P500.

Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.20, from 1.5 in 2017Q1. It dropped, as 30 investors sold SGEN shares while 75 reduced holdings. 48 funds opened positions while 89 raised stakes. 137.48 million shares or 0.82% less from 138.62 million shares in 2017Q1 were reported. Sumitomo Mitsui Holding invested in 308,874 shares or 0.02% of the stock. Tocqueville Asset Management Limited Partnership holds 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 27,190 shares. Moreover, Royal Commercial Bank Of Canada has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 197,348 shares. Mitsubishi Ufj Tru And Bk accumulated 1.01M shares. Bridgewater Lp holds 0.05% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 106,760 shares. Voya reported 36,892 shares. Atria owns 5,427 shares. Price T Rowe Assocs Md, a Maryland-based fund reported 3.85M shares. Proshare Advsr Limited Liability holds 0.04% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 75,284 shares. Moreover, American Century has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 9,816 shares. 40,343 were accumulated by State Of Wisconsin Board. Capstone Inv Limited Liability accumulated 31,700 shares or 0.04% of the stock. University Of Notre Dame Du Lac accumulated 39,295 shares. Argentiere Ag holds 30,000 shares. Sterling Cap Mgmt Limited Co owns 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 4,818 shares.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 11 Hold. Therefore 39% are positive. Seattle Genetics had 56 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Overweight” rating given on Thursday, February 4 by Barclays Capital. The stock has “Hold” rating by Oppenheimer on Thursday, June 15. Piper Jaffray maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating on Friday, October 27. Piper Jaffray has “Hold” rating and $55.0 target. H.C. Wainwright maintained the shares of SGEN in report on Monday, June 19 with “Buy” rating. The rating was maintained by Barclays Capital on Wednesday, July 27 with “Overweight”. The rating was maintained by Needham with “Buy” on Monday, June 19. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Hold” rating by Cowen & Co on Monday, June 19. The stock has “Hold” rating by Oppenheimer on Tuesday, October 10. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, July 31 report. The rating was upgraded by Piper Jaffray on Friday, October 30 to “Neutral”.

The Dun & Bradstreet Corporation provides commercial data, analytics, and insights on businesses worldwide. The company has market cap of $4.48 billion. It offers risk management solutions, including DNBi and D&B Credit, which are subscription based online applications that provide clients real time access to global information, monitoring, and portfolio analysis; various business information reports; D&B Direct, an application programming interface that enables data integration inside enterprise resource planning applications, and master data management and toolkit; credit monitoring solutions; Supplier Risk Manager, an online application, which helps businesses to mitigate supply chain risk; and Onboard and Compliance Check that are online applications that help clients comply with anti-money laundering. It has a 23.35 P/E ratio. The firm also offers sales and marketing solutions, such as customer data management solutions to clean, identify, link, and enrich customer information; D&B Optimizer solution that transforms customer prospects and data into commercial insight; Hoover's that provides information on public and private companies, industries and executives, sales, and marketing and research professionals; Market Insight tools that enable clients to understand existing clients in order to create campaigns to cross-sell new business; Audience Solutions, which enable advertisers and companies to target professionals in various ways; and various other marketing solutions.

The stock increased 0.74% or $0.89 during the last trading session, reaching $121.33. About 105,247 shares traded. The Dun & Bradstreet Corporation (NYSE:DNB) has declined 12.51% since December 7, 2016 and is downtrending. It has underperformed by 29.21% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com